Corcept’s Lifyorli wins early FDA approval for ovarian cancer

AI Briefing

• – FDA approves Corcept's relacorilant for ovarian cancer
• – Relacorilant has a mechanism of action that targets the glucocorticoid receptor
• – Approval comes nearly four months ahead of schedule for adults with platinum-resistant ovarian cancer